Income Statement (TTM)
Provectus Biopharmaceuticals, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Change (%) | 171.48 | 61.83 | 20.00 | 1.76 | -15.88 | -28.96 | -7.27 | 5.93 | 15.77 | 5.85 | -14.75 | 6.57 | -30.03 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Change (%) | 8.16 | -0.94 | -15.17 | -5.27 | -16.14 | -12.54 | 5.85 | 0.45 | 2.65 | 3.58 | 7.75 | -8.50 | 22.58 | |
| % of Revenue | 1,354.90 | 539.82 | 330.44 | 233.60 | 217.46 | 216.80 | 266.91 | 304.69 | 288.93 | 256.18 | 250.69 | 316.87 | 272.04 | 476.58 |
| Gross Operating Profit | -2 | -2 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 |
| Change (%) | -4.85 | -15.21 | -30.43 | -10.53 | -16.35 | 1.52 | 13.72 | -2.23 | -4.30 | 2.13 | 22.69 | -15.46 | 53.15 | |
| % of Revenue | -1,254.90 | -439.82 | -230.44 | -133.60 | -117.46 | -116.80 | -166.91 | -204.69 | -188.93 | -156.18 | -150.69 | -216.87 | -172.04 | -376.58 |
| SG&A | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 4 |
| Change (%) | -2.61 | -1.94 | -23.74 | -1.69 | -21.17 | -3.23 | 16.88 | -31.41 | 6.47 | 9.09 | 141.29 | 35.02 | 12.08 | |
| % of Revenue | 1,132.99 | 406.45 | 246.29 | 156.52 | 151.21 | 141.70 | 193.01 | 243.28 | 157.52 | 144.86 | 149.29 | 422.56 | 535.37 | 857.56 |
| R&D | ||||||||||||||
| Change (%) | ||||||||||||||
| % of Revenue | ||||||||||||||
| OpEx | 5 | 5 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 6 |
| Change (%) | 3.26 | -1.37 | -18.83 | -3.83 | -18.20 | -8.86 | 10.48 | -13.70 | 3.99 | 5.57 | 57.60 | 16.37 | 15.61 | |
| % of Revenue | 2,487.89 | 946.27 | 576.73 | 390.12 | 368.66 | 358.50 | 459.92 | 547.97 | 446.45 | 401.04 | 399.98 | 739.43 | 807.41 | 1,334.14 |
| Operating Income | -4 | -4 | -4 | -3 | -3 | -2 | -2 | -2 | -2 | -2 | -2 | -4 | -5 | -6 |
| Change (%) | -3.79 | -8.84 | -26.97 | -5.76 | -19.07 | -1.08 | 15.41 | -18.08 | 0.60 | 5.48 | 81.71 | 17.90 | 22.07 | |
| % of Revenue | -2,387.89 | -846.27 | -476.73 | -290.12 | -268.66 | -258.50 | -359.92 | -447.97 | -346.45 | -301.04 | -299.98 | -639.43 | -707.41 | -1,234.14 |
| Interest Expense | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | -82.40 | 48.44 | 24.47 | 8.78 | 7.13 | 7.91 | 5.03 | 5.34 | 4.60 | -1.19 | 1.57 | 2.88 | -4.04 | |
| % of Revenue | -268.27 | -17.40 | -15.96 | -16.55 | -17.69 | -22.53 | -34.23 | -38.77 | -38.55 | -34.83 | -32.51 | -38.74 | -37.40 | -51.29 |
| Net Income | -5 | -4 | -4 | -4 | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -5 | -5 | -6 |
| Change (%) | -10.24 | -7.68 | -12.46 | -5.72 | -7.24 | 2.01 | -2.18 | -10.43 | 0.42 | 8.55 | 57.24 | 13.36 | 17.92 | |
| % of Revenue | -2,612.15 | -863.66 | -492.69 | -359.41 | -332.97 | -367.17 | -527.24 | -556.16 | -470.30 | -407.97 | -418.37 | -771.65 | -820.77 | -1,383.31 |
Source: Capital IQ
